

# World Journal of *Clinical Cases*

*World J Clin Cases* 2023 May 6; 11(13): 2855-3113



## Contents

Thrice Monthly Volume 11 Number 13 May 6, 2023

## OPINION REVIEW

- 2855 Long-term implications of fetal growth restriction  
*D'Agostin M, Di Sipio Morgia C, Vento G, Nobile S*

## REVIEW

- 2864 Appraisal of gastric stump carcinoma and current state of affairs  
*Shukla A, Kalayarasan R, Gnanasekaran S, Pottakkat B*
- 2874 Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit  
*Pace MC, Corrente A, Passavanti MB, Sansone P, Petrou S, Leone S, Fiore M*

## MINIREVIEWS

- 2890 Individualized diabetes care: Lessons from the real-world experience  
*Khor XY, Pappachan JM, Jeeyavudeen MS*
- 2903 Clinical management of dural defects: A review  
*Dong RP, Zhang Q, Yang LL, Cheng XL, Zhao JW*
- 2916 Potential impact of music interventions in managing diabetic conditions  
*Eseadi C, Amedu AN*
- 2925 Implications of obesity and adiposopathy on respiratory infections; focus on emerging challenges  
*Lempesis IG, Georgakopoulou VE*

## ORIGINAL ARTICLE

## Case Control Study

- 2934 Association of C-reactive protein and complement factor H gene polymorphisms with risk of lupus nephritis in Chinese population  
*Li QY, Lv JM, Liu XL, Li HY, Yu F*

## Retrospective Study

- 2945 Comparison of the application value of transvaginal ultrasound and transabdominal ultrasound in the diagnosis of ectopic pregnancy  
*Hu HJ, Sun J, Feng R, Yu L*

## Observational Study

- 2956 Assessment of knowledge, cultural beliefs, and behavior regarding medication safety among residents in Harbin, China  
*Liu XT, Wang N, Zhu LQ, Wu YB*

## SYSTEMATIC REVIEWS

- 2966 Palliative oral care in terminal cancer patients: Integrated review  
*Silva ARP, Bodanezi AV, Chrun ES, Lisboa ML, de Camargo AR, Munhoz EA*

## META-ANALYSIS

- 2981 Effect of preoperative inspiratory muscle training on postoperative outcomes in patients undergoing cardiac surgery: A systematic review and meta-analysis  
*Wang J, Wang YQ, Shi J, Yu PM, Guo YQ*
- 2992 Efficacy and safety of intravenous tranexamic acid in total shoulder arthroplasty: A meta-analysis  
*Deng HM*

## CASE REPORT

- 3002 Awake laparoscopic cholecystectomy: A case report and review of literature  
*Mazzone C, Sofia M, Sarv  I, Litrico G, Di Stefano AML, La Greca G, Latteri S*
- 3010 Bilateral malignant glaucoma with bullous keratopathy: A case report  
*Ma YB, Dang YL*
- 3017 Finger compartment syndrome due to a high-pressure washer injury: A case report  
*Choi JH, Choi SY, Hwang JH, Kim KS, Lee SY*
- 3022 Primary dedifferentiated chondrosarcoma of the lung with a 4-year history of breast cancer: A case report  
*Wen H, Gong FJ, Xi JM*
- 3029 Importance of proper ventilator support and pulmonary rehabilitation in obese patients with heart failure: Two case reports  
*Lim EH, Park SH, Won YH*
- 3038 Multiple flexor tendon ruptures due to osteochondroma of the hamate: A case report  
*Kwon TY, Lee YK*
- 3045 Fractional flow reserve measured *via* left internal mammary artery after coronary artery bypass grafting: Two case reports  
*Zhang LY, Gan YR, Wang YZ, Xie DX, Kou ZK, Kou XQ, Zhang YL, Li B, Mao R, Liang TX, Xie J, Jin JJ, Yang JM*
- 3052 Uterine artery embolization combined with percutaneous microwave ablation for the treatment of prolapsed uterine submucosal leiomyoma: A case report  
*Zhang HL, Yu SY, Cao CW, Zhu JE, Li JX, Sun LP, Xu HX*
- 3062 Metachronous urothelial carcinoma in the renal pelvis, bladder, and urethra: A case report  
*Zhang JQ, Duan Y, Wang K, Zhang XL, Jiang KH*
- 3070 Unusual phenomenon-“polyp” arising from a diverticulum: A case report  
*Liew JJJ, Lim WS, Koh FH*

- 3076** Idiopathic steno-occlusive disease with bilateral internal carotid artery occlusion: A Case Report  
*Hamed SA, Yousef HA*
- 3086** Solitary acral persistent papular mucinosis nodule: A case report and summary of eight Korean cases  
*Park YJ, Shin HY, Choi WK, Lee AY, Lee SH, Hong JS*
- 3092** Eosinophilic fasciitis difficult to differentiate from scleroderma: A case report  
*Lan TY, Wang ZH, Kong WP, Wang JP, Zhang N, Jin DE, Luo J, Tao QW, Yan ZR*
- 3099** Misdiagnosis of scalp angiosarcoma: A case report  
*Yan ZH, li ZL, Chen XW, Lian YW, Liu LX, Duan HY*
- 3105** Discrepancy among microsatellite instability detection methodologies in non-colorectal cancer: Report of 3 cases  
*Şenocak Taşçı E, Yıldız İ, Erdamar S, Özer L*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Jina Yun, MD, PhD, Assistant Professor, Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon 14584, South Korea. 19983233@schmc.ac.kr

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Si Zhao; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

May 6, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Case Control Study

# Association of C-reactive protein and complement factor H gene polymorphisms with risk of lupus nephritis in Chinese population

Qiu-Yu Li, Jian-Min Lv, Xiao-Ling Liu, Hai-Yun Li, Feng Yu

**Specialty type:** Medicine, research and experimental

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): D  
Grade E (Poor): 0

**P-Reviewer:** Reda R, Italy; Tanaka H, Japan

**Received:** September 16, 2022

**Peer-review started:** September 16, 2022

**First decision:** October 11, 2022

**Revised:** October 25, 2023

**Accepted:** February 21, 2023

**Article in press:** February 21, 2023

**Published online:** May 6, 2023



**Qiu-Yu Li**, Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China

**Jian-Min Lv**, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China

**Xiao-Ling Liu**, School of Life Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Hai-Yun Li**, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China

**Feng Yu**, Department of Medicine, Peking University First Hospital, Beijing 100034, China

**Corresponding author:** Hai-Yun Li, PhD, Assistant Professor, School of Basic Medical Sciences, Xi'an Jiaotong University, No. 76 Yanta West Road, Xi'an 710061, Shaanxi Province, China. [lihaiy@xjtu.edu.cn](mailto:lihaiy@xjtu.edu.cn)

## Abstract

### BACKGROUND

Complement overactivation is a major driver of lupus nephritis (LN). Impaired interactions of C-reactive protein (CRP) with complement factor H (CFH) have been shown as a pathogenic mechanism that contributes to the overactivation of complement in LN. However, genetic variations of neither CRP nor CFH show consistent influences on the risk of LN.

### AIM

To examine whether genetic variations of CRP and CFH in combination can improve the risk stratification in Chinese population.

### METHODS

We genotyped six CRP single nucleotide polymorphisms (SNPs) (rs1205, rs3093062, rs2794521, rs1800947, rs3093077, and rs1130864) and three CFH SNPs (rs482934, rs1061170, and rs1061147) in 270 LN patients and 303 healthy subjects.

### RESULTS

No linkage was found among CRP and CFH SNPs, indicating lack of genetic interactions between the two genes. Moreover, CRP and CFH SNPs, neither individually nor in combination, are associated with the risk or clinical manifest-

ations of LN. Given the unambiguous pathogenic roles of the two genes.

### CONCLUSION

These findings suggest that the biological effects of most genetic variations of CRP and CFH on their expressions or activities are not sufficient to influence the disease course of LN.

**Key Words:** Systemic lupus erythematosus; Lupus nephritis; C-reactive protein; Complement factor H; Single nucleotide polymorphism.

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In spite of the unambiguous pathogenic roles of C-reactive protein (CRP) and complement factor H (CFH) in lupus nephritis (LN), our present study involving a Chinese population has failed to reveal any significant associations of their genetic variations with LN risk. These findings suggest that most genetic variations of CRP and CFH might possess limited biological effects on their expressions or activities and are thus not sufficient to influence the disease course of LN. Overall, we concluded that genetic variations of CRP and CFH could not be used to improve the risk stratification of LN in Chinese population.

**Citation:** Li QY, Lv JM, Liu XL, Li HY, Yu F. Association of C-reactive protein and complement factor H gene polymorphisms with risk of lupus nephritis in Chinese population. *World J Clin Cases* 2023; 11(13): 2934-2944

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i13/2934.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v11.i13.2934>

### INTRODUCTION

As an autoimmune disease, the pathogenesis of systemic lupus erythematosus (SLE) involves clearance defect of apoptotic cells, uncontrolled activation of complement and massive production of autoantibodies[1,2]. Previously studies have shown that 40% of SLE patients have clinical manifestations of renal dysfunction and that about 80% of SLE patients have different degrees of pathological renal damage, including lupus nephritis (LN), a common and severe complication of SLE, which is regarded as the main factor for the poor prognosis of patients[3-5].

reactive protein (CRP) is an acute phase reactant and a commonly used clinical marker of inflammation[6-10]. Besides, CRP could promote the elimination of damaged cells or pathogens by activating and regulating the complement system. Previous clinical studies suggest that CRP and SLE/LN have certain correlations. Firstly, CRP gene locates in the chromosome 1q23, an SLE linkage region[11,12]. Secondly, elevation of CRP levels is generally impaired in SLE patients especially those with kidney and skin involvement[13]. Thirdly, CRP autoantibodies can be detected in a considerable number of patients, which may relate to abnormal plasma levels in SLE[14-16]. Lastly, several animal studies on lupus-prone mouse strain (NZB/NZW) revealed that human CRP could help to produce less proteinuria and prolonged survival[17-19]. In the past decades, studies have been made to clarify the associations of CRP Single Nucleotide Polymorphisms (SNPs) with SLE susceptibility, while conclusions remained inconsistent[20-24]. Moreover, no CRP SNPs studies have been performed in the Chinese population.

In addition to CRP, complement factor H (CFH), a factor that negatively regulates alternative complement pathway, is another candidate associated with SLE. Firstly, CFH deficiency has been proven to accelerate the development of LN[25], and serum CFH level was observed to be associated with clinical and pathological activities of SLE patients with LN[26]. Secondly, several families suffering from SLE were reported to possess CFH deficiency or mutations[27,28]. Genetic variations of CFH can sometimes affect its bioactivities, in which several exotic SNPs were found to be related to various human diseases[29]. Among CFH SNPs, rs1061170 corresponds to a CFH variant Tyr402His, which exhibits impaired CFH-CRP binding efficiency. Because CRP could inhibit the complement overactivation by recruiting CFH, so Tyr402His theoretically results in dysregulated complement activation[30].

Despite that LN is a complement-related disease, and that both CRP and CFH are involved in complement regulation, it remains unclear whether CRP and CFH SNPs directly impact the pathogenesis of LN. In this scenario, we carried out the present study, in which six CRP SNPs and three CFH SNPs were genotyped in 270 LN patients and 303 healthy controls of a Chinese cohort. Association analysis was subsequently performed for these SNPs and LN risk from the perspectives of allele, genotype, combined SNPs and haplotype. As far as we know, this is the first study to consider SNPs of CRP and CFH together when evaluating their relationship with LN risk in the Chinese population. Our data show that SNPs of both genes have no significant association with LN risk. Given the



unambiguous pathogenic role of the two genes, these findings suggest that the biological effects of genetic variations of CRP and CFH on their expression or activities are not sufficient to influence the disease course of LN in the Chinese population.

## MATERIALS AND METHODS

### Participants

Renal histopathological data of 270 patients with renal biopsy-proven LN, diagnosed between January 2000 and July 2017 in Peking University First Hospital, were reviewed and reclassified according to the International Society of Nephrology and Renal Pathology Society (ISN/RPS) 2003 classification[31]. 303 age and gender matched healthy controls were collected. The work was approved by the Ethics Committee of Peking University First Hospital [Approval No. 2017(1333)].

### DNA Preparation and SNP Genotyping.

Blood samples of the 270 SLE patients and 303 healthy controls of Chinese Han individuals were collected with the approval of the Ethics Committee of Peking University First Hospital. Human genomic DNA was extracted using Qiagen Blood DNA Kit (QIAGEN China, Shanghai) according to the manufacturer's instructions. Subsequently, the CRP SNPs (rs1205, rs3093077, rs3091244, rs1130864, rs1800947, rs2794521), and CFH SNPs (rs1061170, rs482934 and rs1061147) was genotyped by SNaPshot (ABI PRISM® SNaPshot™ Multiplex Kit, ABI) with specific primers.

### Evaluation of Clinical, Laboratory and Renal Pathological Indexes of LN Patients

For clinical evaluation, the disease activities of all patients were assessed by the SLE Disease Activity Index[32,33]. Briefly, the following items were collected and analyzed: Sex, fever, malar rash, photosensitivity, oral ulcer, alopecia, arthritis, serositis, neurologic disorder, anemia, leukocytopenia, thrombocytopenia, hematuria, and leukocyturia. For laboratory assessment, the following items were collected as we previously reported[34]: Complete blood count, plasma lactate dehydrogenase, liver enzymes, peripheral blood smear, urine analysis, serum creatinine, serum antinuclear antibodies, anti-double-stranded DNA antibodies, anti-extractable nuclear antigen antibodies, anti-cardiolipin antibodies and C3. For renal histopathology, all renal biopsy specimens were examined by light microscopy, direct immunofluorescence, and electron microscopy techniques as our previous reports [35]. All samples were double-blind reviewed by two experienced pathologists based on the 2003 ISN/RPS recommendation on LN classification[36]. The pathologists classified and scored the biopsies separately, especially for the activity indices, chronicity indices. Differences in scoring between pathologists were resolved by re-reviewing the biopsies and thus reaching a consensus. Renal histopathological data of 270 LN patients was classified according to the ISN/RPS 2003 classification, which was an improved version of World Health Organization (WHO)[37].

### Statistical Analysis

Hardy-Weinberg equilibrium testing was performed for all healthy controls using a chi-squared test. Distributions of genotype, allele and haplotype were compared between control and case groups using Pearson's chi-squared test or Fisher's exact test. For comparison of clinical, laboratory and pathological features of patients, student's *t*-test and one way analysis of variance (ANOVA) were used. A *P* value less than 0.05 was considered to be significant. Pairwise Linkage Disequilibrium (LD) and haplotype analysis were both conducted using the SHEs platform[38]. SNP pairs with *D'* value great than 0.8 and *r*<sup>2</sup> value great than 0.33 were considered to be in significant LD. Meta-analysis was performed by using Stata 15 software. Relative risks of SLE/LN were estimated according to ORs with 95% CIs. The inconsistency index *I*<sup>2</sup> was calculated to quantify the heterogeneity: If *I*<sup>2</sup> < 50%, suggesting that the degree of heterogeneity was low, and the meta-analysis was performed using the fixed effect model; otherwise, the random effects model was used. *P* > 0.05 means no statistical significance.

## RESULTS

### Association of CRP SNPs and haplotypes with LN risk

Six CRP SNPs (rs1205, rs3093077, rs3091244, rs1130864, rs1800947 and rs2794521) were genotyped in 270 LN patients and 303 healthy controls (Figure 1). Chi-squared test showed that genotype frequency distributions of CRP SNPs in all healthy controls were all in Hardy-Weinberg equilibrium (Supplementary Table 1). In subsequent comparisons of case and control groups (Table 1), none of the alleles or genotypes was observed to be significantly associated with the SLE risk (*P* > 0.05). In further analysis, we examined the effects of CRP SNP combinations, and again failed to observe any significant difference in genotype distributions of LN patients and healthy controls (Supplementary Table 2).



**Table 1 Genotype and allele frequencies of C-reactive protein single nucleotide polymorphisms, *n* (%)**

Genotype	LN	Normal	P value	Allele	LN	Normal	P value
rs1205 (C>T)							
CC	53 (19.63)	49 (16.17)	0.469	C	245 (45.37)	254 (41.91)	0.239
CT	139 (51.48)	156 (51.49)		T	295 (54.63)	352 (58.09)	
TT	78 (28.89)	98 (32.34)					
rs3093077 (A>C)							
AA	173 (64.07)	208 (68.65)	0.436	A	436 (80.74)	502 (82.84)	0.358
AC	90 (33.33)	86 (28.38)		C	104 (19.26)	104 (17.16)	
CC	7 (2.59)	9 (2.97)					
rs3091244 (C>T>A)							
CC	153 (56.67)	180 (59.41)	0.935 <sup>1</sup>	C	410 (75.93)	467 (77.06)	0.712
CT	23 (8.52)	28 (9.24)		T	29 (5.37)	36 (5.94)	
CA	81 (30.00)	79 (26.07)		A	101 (18.70)	103 (17.00)	
TT	1 (0.37)	1 (0.33)					
TA	4 (1.48)	6 (1.98)					
AA	8 (2.96)	9 (2.97)					
rs1130864 (G>A)							
GG	241 (89.26)	270 (89.11)	0.797 <sup>1</sup>	G	509 (94.26)	572 (94.39)	0.924
GA	27 (10.00)	32 (10.56)		A	31 (5.74)	34 (5.61)	
AA	2 (0.74)	1 (0.33)					
rs1800947 (C>G)							
CC	245 (90.74)	273 (90.10)	1.000 <sup>1</sup>	C	515 (95.37)	575 (94.88)	0.703
CG	25 (9.26)	29 (9.57)		G	25 (4.63)	31 (5.12)	
GG	0 (0.00)	1 (0.33)					
rs2794521 (T>C)							
TT	187 (69.26)	222 (73.27)	0.177	T	446 (82.59)	520 (85.81)	0.135
TC	72 (26.67)	76 (25.08)		C	94 (17.41)	86 (14.19)	
CC	11 (4.07)	5 (1.65)					

<sup>1</sup>Fisher's exact test; unmarked, Pearson's chi-squared test.

LN: Lupus nephritis.

Subsequently, pairwise LD analysis was conducted for CRP SNPs in healthy controls. Of all SNP pairs, rs3091244/rs3093077 and rs3091244/rs1205 pairs were found to be in significant LD (Table 2). Considering that SNP haplotype may provide more informative details, CRP haplotypes were thus included for further investigation. Given the acceptable number, we included all 6 CRP SNPs in the haplotype analysis. Finally, 6 CRP haplotypes were observed at frequencies greater than 3.0% in both healthy controls and LN patients. However, no significant differences were found in the distribution frequencies of those haplotypes between the two groups (Table 3).

To further confirm whether these CRP SNPs are indeed unrelated to LN in the present population, we thus further checked the association of these SNPs with clinical, laboratory and pathological features of all patients (Supplementary Tables 3-6). In line with the conclusions above, most indexes exhibited no significant differences between genotypes of these SNPs. Notably, WHO classification for all LN patients was performed and association between pathological subclass and SNPs were further analyzed, whereas no significant differences were observed. However, several items showed differences, which might imply potential relevance of these SNPs with LN to some extent, suggesting that conclusion should cautiously draw.

**Table 2 Pairwise linkage disequilibrium analysis of C-reactive protein single nucleotide polymorphisms in healthy controls**

r <sup>2</sup>  D'	rs3093077	rs1205	rs1130864	rs1800947	rs3091244	rs2794521
rs3093077		1.000	0.990	0.985	<b>0.979</b>	0.748
rs1205	0.278		0.999	0.999	<b>0.984</b>	1.000
rs1130864	0.012	0.082		0.986	1.000	0.974
rs1800947	0.011	0.039	0.003		0.993	0.986
rs3091244	<b>0.675</b>	<b>0.360</b>	0.212	0.014		0.996
rs2794521	0.019	0.229	0.009	0.009	0.044	

D' and r<sup>2</sup> are listed on the top right and lower left, respectively. Bold represents pairs with D' values great than 0.8 and r<sup>2</sup> values great than 0.33.

**Table 3 Association of C-reactive protein haplotypes with risk of lupus nephritis**

CRP haplotypes and their frequencies in SLE and normal controls					
CRP haplotype		SLE-freq (% , n = 270)	Normal-freq (% , n = 303)	$\chi^2$	Overall P value
H1	G G G G T A	17.8	16.7	3.293	0.655
H2	T A G C G A	4.3	5.1		
H3	T A G G G A	50.2	52.8		
H4	T G A G A A	5.4	5.6		
H5	T G G G G A	4.1	5.1		
H6	T G G G G G	16.6	13.7		

Single nucleotide polymorphism order in the haplotypes is arranged according to their positions in the chromosome (rs3093077, rs1205, rs1130864, rs1800947, rs3091244, rs2794521). Only the significant haplotypes (frequency > 3.0%) are shown. CRP: C-reactive protein; SLE: Systemic lupus erythematosus.

### Association of CFH SNPs and haplotypes with LN risk

Similarly, we subsequently genotyped 3 CFH SNPs, namely rs1061170, rs482934 and rs1061147, in 270 LN patients and 303 healthy controls (Figure 1). After Hardy-Weinberg equilibrium was checked for all genotype frequencies of controls (Supplementary Table 7), association of CFH polymorphism with LN risk were examined. Of note, no significant enrichment or depletion of allele and genotype distribution has been observed in LN patients (Table 4). In further exploration, pairwise LD for those CFH SNPs was examined as before. Dramatically, all three SNP pairs were found to be in strong LD (Table 5). Based on this, haplotype analysis was conducted, in which two CFH haplotypes were observed at frequencies greater than 3.0% in both healthy controls and LN patients. However, no significant associations were found between those two haplotypes and LN risk (Table 6).

In further analysis, we checked the association of rs1061170 with clinical, laboratory and pathological features of all LN patients (Supplementary Table 8). Similar to CRP SNPs, except for a few items, most indexes exhibited no significant differences between genotypes of these SNPs.

### Association of CRP-CFH SNP combinations with LN risk

Given the key roles of complement overactivation in SLE pathogenesis and the capacity of CRP to inhibit this process *via* interaction with CFH, we next asked whether any potential associations could be found in SNP combinations of CRP and CFH. Specifically, CFH SNP rs1061170, which corresponds to a variant Tyr402His with impaired capacity to bind CRP[39,40], was combined with 6 CRP SNPs and evaluated individually. However, we failed to observe any significant associations in all SNP combinations included (Table 7). Besides, cross pairs of the CRP and CFH SNPs were further included for pairwise LD evaluation, in which no significant LD was observed (Supplementary Table 9).

## DISCUSSION

In the past decades, studies have been focused on revealing the associations of CRP/CFH genetic variations with SLE/LN[41]. However, those studies were mainly based on the European or American populations, and often gained inconsistent conclusions. Moreover, although CRP/CFH interaction

**Table 4 Genotype and allele frequencies of complement factor H single nucleotide polymorphisms, *n* (%)**

Genotype	LN	Normal	<i>P</i> value	Allele	LN	Normal	<i>P</i> value
rs1061170 (T>C)							
TT	235 (87.04)	258 (85.15)	0.220 <sup>1</sup>	T	503 (93.15)	561 (92.57)	0.707
TC	33 (12.22)	45 (14.85)		C	37 (6.85)	45 (7.43)	
CC	2 (0.74)	0 (0.00)					
rs482934 (A>C)							
AA	236 (87.41)	258 (85.15)	0.189 <sup>1</sup>	A	504 (0.93)	561 (0.93)	0.617
AC	32 (11.85)	45 (14.85)		C	36 (0.07)	45 (0.07)	
CC	2 (0.74)	0 (0.00)					
rs1061147 (C>A)							
CC	235 (87.04)	257 (84.82)	0.194 <sup>1</sup>	C	503 (0.93)	560 (0.92)	0.63
CA	33 (12.22)	46 (15.18)		A	37 (0.07)	46 (0.08)	
AA	2 (0.74)	0 (0.00)					

<sup>1</sup>Fisher's exact test; unmarked, Pearson's chi-squared test.

LN: Lupus nephritis.

**Table 5 Pairwise linkage disequilibrium analysis of complement factor H single nucleotide polymorphisms in healthy controls**

r <sup>2</sup> /D'	rs1061147	rs482934	rs1061170
rs1061147		0.976	1.000
rs482934	0.930		0.976
rs1061170	0.977	0.952	

D' and r<sup>2</sup> are listed on the top right and lower left, respectively. Bold represents pairs with D' values great than 0.8 and r<sup>2</sup> values great than 0.33.**Table 6 Association of complement factor H haplotypes with risk of lupus nephritis**

CRP Haplotype	LN-freq (% <i>n</i> = 270)	Normal-freq (% <i>n</i> = 303)	χ <sup>2</sup>	Overall <i>P</i> value
H1 A C G	6.3	7.3	0.426	0.514
H2 C A A	93.3	92.2		

SNP order in the haplotypes is arranged according to their positions in the chromosome.

CRP: C-reactive protein; LN: Lupus nephritis.

theoretically plays a role in LN pathogenesis, they have not been considered together when evaluating the association of their genetic variations with the LN risk.

In this study, we enrolled 6 CRP SNPs and 3 CFH SNPs of a Chinese cohort, and studied their relationship with LN risk, which has not yet been systematically reported. Our study revealed that there were no significant associations between these SNPs and LN susceptibility in the Chinese population. All patients in this study were selected from the same center and their diagnosis were all confirmed by renal biopsy. Moreover, the complete clinical, laboratory and pathological indexes were also included to test the results. Therefore, although no statistical associations were observed in our study, valid and useful information could still be revealed.

In addition, these negative results are generally consistent with the conclusions of previous researches to a large extent. Among the 6 CRP SNPs, rs1800947[20,24-26] and rs2794521[23,25] were included in several studies, which were repeatedly reported to be unrelated to SLE in various populations, consistent with our results. For rs1205[20,21,24-26], rs3091244[20,21,24,25] and rs1130864 [20-22], conclusions remained inconsistent among these studies, which might rationalize the existence of our negative results to some extent. For the CFH SNPs, Zhao *et al* [29] evaluated an Asian group


**Table 7 Genotype frequencies of combined single nucleotide polymorphisms of C-reactive protein and complement factor H, *n* (%)**

CRP-CFH genotype combination	LN	Normal	<i>P</i> value
rs1205 + rs1061170			
CCTT	46 (17.10)	45 (14.85)	0.105
CCTC	7 (2.60)	4 (1.32)	
CTTT	124 (46.10)	125 (41.25)	
CTTC	14 (5.20)	31 (10.23)	
TTTT	65 (24.16)	88 (29.04)	
TTTC	13 (4.83)	10 (3.30)	
rs3093077 + rs1061170			
AATT	150 (56.39)	180 (59.80)	0.322
AATC	23 (8.65)	28 (9.30)	
ACTT	81 (30.45)	71 (23.59)	
ACTC	8 (3.01)	15 (4.98)	
CCTT	4 (1.50)	7 (2.33)	
rs3091244 + rs1061170			
CCTT	133 (50.57)	155 (52.19)	0.756
CCTC	21 (7.98)	25 (8.42)	
CTTT	21 (7.98)	25 (8.42)	
CATT	71 (27.00)	64 (21.55)	
CATC	9 (3.42)	15 (5.05)	
TATT	4 (1.52)	6 (2.02)	
AATT	4 (1.52)	7 (2.36)	
rs1130864 + rs1061170			
GGTT	208 (78.49)	228 (76.25)	0.772
GGTC	32 (12.08)	42 (14.05)	
GATT	25 (9.43)	29 (9.70)	
rs1800947 + rs1061170			
CCTT	214 (80.75)	232 (77.85)	0.655
CCTC	30 (11.32)	41 (13.76)	
CGTT	21 (7.92)	25 (8.39)	
rs2794521 + rs1061170			
TTTT	160 (59.93)	187 (61.92)	0.431
TTTC	26 (9.74)	35 (11.59)	
TCTT	66 (24.72)	67 (22.19)	
TCTC	6 (2.25)	9 (2.98)	
CCTT	9 (3.37)	4 (1.32)	

Pearson's chi-squared test.

CRP: C-reactive protein; CFH: Complement factor H; LN: Lupus nephritis.

involving 200 Chinese SLE cases and found no significant association between rs1061147 and SLE (without LN). Tan *et al*[41] enrolled 334 LN patients, 269 SLE patients without LN and 350 healthy controls from China, but failed to observe any significant differences in allele and genotype frequencies of rs1061170 among groups. Both conclusions were consistent with our present findings.



**Figure 1** Polymorphisms schematic diagram and the clinical characteristics of patients with lupus nephritis. A: Polymorphisms in the C-reactive protein (CRP) and complement factor H (CFH) gene, six single nucleotide polymorphisms (SNPs) in CRP and three SNPs in CFH were selected; B: Clinical characteristics of patients with lupus nephritis. CRP: C-reactive protein; CFH: Complement factor H; SNP: Single nucleotide polymorphisms; UTR: Untranslated regions.

Given that interaction of CRP and CFH would theoretically help to regulate complement and therefore play roles in SLE/LN pathogenesis, we combined 6 CRP SNPs individually with CFH SNP rs1061170, which corresponds to a CFH variant with impaired capacity in CRP binding. To our knowledge, this is the first study to combine these two genes when performing a correlation analysis with LN risk. However, we still failed to observe any significant associations from this perspective.

Overall, our results suggest that CRP and CFH genetic variation and interaction do not affect the occurrence of LN at the gene level in a Chinese population. In future studies, multiple-center sampling is needed to expand the study scale, whereas SLE patients without LN from other rheumatism departments should also be included. Moreover, more SNPs should be examined for these two genes, while other molecules along the pathogenesis pathway of CRP and CFH should be involved for a joint analysis.

## CONCLUSION

In spite of the unambiguous pathogenic roles of CRP and CFH in LN, our present study involving a Chinese population has failed to reveal any significant associations of their genetic variations with LN risk. These findings suggest that most genetic variations of CRP and CFH might possess limited biological effects on their expressions or activities, and are thus not sufficient to influence the disease course of LN. Overall, we concluded that genetic variations of CRP and CFH could not be used to improve the risk stratification of LN in Chinese population.

## ARTICLE HIGHLIGHTS

### Research background

Both C-reactive protein (CRP) and complement factor H (CFH) play roles in pathogenesis of lupus

nephritis (LN).

### **Research motivation**

It still keeps unclear whether genetic variations of CRP and CFH are involved in risk of LN.

### **Research objectives**

To examine whether genetic variations of CRP and CFH are associated with the susceptibility to LN in the Chinese population.

### **Research methods**

A case control study was conducted, in which six CRP Single Nucleotide Polymorphisms (SNPs) and three CFH SNPs were genotyped and analysed in 270 LN patients and 303 healthy subjects.

### **Research results**

CRP and CFH SNPs, neither individually nor in combination, are associated with the risk or clinical manifestations of LN. Moreover, no linkage was found among CRP and CFH SNPs, indicating lack of genetic interactions between the two genes.

### **Research conclusions**

Biological effects of most genetic variations of CRP and CFH on their expressions or activities are not sufficient to influence the disease course of LN.

### **Research perspectives**

Future studies involving multiple-center sampling are needed to expand the study scale. Moreover, more SNPs should be examined for these two genes, while other molecules along the pathogenesis pathway of CRP and CFH should be involved for a joint analysis.

---

## **FOOTNOTES**

**Author contributions:** Yu F and Li HY designed the research. Li QY, Lv JM, and Liu XL performed the experiments. Lv JM and Li HY analyzed the data and wrote the paper. All authors reviewed and approved the final version of the manuscript.

**Institutional review board statement:** The work was approved by the Ethics Committee of Peking University First Hospital [Approval No. 2017(1333)].

**Informed consent statement:** Informed written consent was obtained from the patient and her family for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest with the contents of this article.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Qiu-Yu Li 0000-0002-8707-5229; Jian-Min Lv 0000-0001-9693-4200; Hai-Yun Li 0000-0002-7458-7399; Feng Yu 0000-0003-3060-6233.

**S-Editor:** Liu GL

**L-Editor:** A

**P-Editor:** Liu GL



## REFERENCES

- 1 **Rahman A**, Isenberg DA. Systemic lupus erythematosus. *N Engl J Med* 2008; **358**: 929-939 [PMID: [18305268](#) DOI: [10.1056/NEJMra071297](#)]
- 2 **Almaani S**, Meara A, Rovin BH. Update on Lupus Nephritis. *Clin J Am Soc Nephrol* 2017; **12**: 825-835 [PMID: [27821390](#) DOI: [10.2215/CJN.05780616](#)]
- 3 **Johannesson B**, Lima G, von Salomé J, Alarcón-Segovia D, Alarcón-Riquelme ME; Collaborative Group on the Genetics of SLE, The BIOMED II Collaboration on the Genetics of SLE and Sjögrens syndrome. A major susceptibility locus for systemic lupus erythematosus maps to chromosome 1q31. *Am J Hum Genet* 2002; **71**: 1060-1071 [PMID: [12373647](#) DOI: [10.1086/344289](#)]
- 4 **Tsao BP**, Cantor RM, Grossman JM, Kim SK, Strong N, Lau CS, Chen CJ, Shen N, Ginzler EM, Goldstein R, Kalunian KC, Arnett FC, Wallace DJ, Hahn BH. Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus. *Arthritis Rheum* 2002; **46**: 2928-2936 [PMID: [12428234](#) DOI: [10.1002/art.10590](#)]
- 5 **Tsao BP**. Update on human systemic lupus erythematosus genetics. *Curr Opin Rheumatol* 2004; **16**: 513-521 [PMID: [15314487](#) DOI: [10.1097/01.bor.0000132648.62680.81](#)]
- 6 **Caprio V**, Badimon L, Di Napoli M, Fang WH, Ferris GR, Guo B, Iemma RS, Liu D, Zeinolabediny Y, Slevin M. pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics. *Front Immunol* 2018; **9**: 1089 [PMID: [29892284](#) DOI: [10.3389/fimmu.2018.01089](#)]
- 7 **Jimenez RV**, Wright TT, Jones NR, Wu J, Gibson AW, Szalai AJ. C-Reactive Protein Impairs Dendritic Cell Development, Maturation, and Function: Implications for Peripheral Tolerance. *Front Immunol* 2018; **9**: 372 [PMID: [29556231](#) DOI: [10.3389/fimmu.2018.00372](#)]
- 8 **Molins B**, Romero-Vázquez S, Fuentes-Prior P, Adan A, Dick AD. C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. *Front Immunol* 2018; **9**: 808 [PMID: [29725335](#) DOI: [10.3389/fimmu.2018.00808](#)]
- 9 **Romero-Vázquez S**, Adán A, Figueras-Roca M, Llorenç V, Slevin M, Vilahur G, Badimon L, Dick AD, Molins B. Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro: implications for age-related macular degeneration. *Aging (Albany NY)* 2020; **12**: 13905-13923 [PMID: [32673285](#) DOI: [10.18632/aging.103655](#)]
- 10 **Zeinolabediny Y**, Kumar S, Slevin M. Monomeric C-Reactive Protein - A Feature of Inflammatory Disease Associated With Cardiovascular Pathophysiological Complications? *In Vivo* 2021; **35**: 693-697 [PMID: [33622861](#) DOI: [10.21873/invivo.12309](#)]
- 11 **Moser KL**, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, Bruner GR, Fox J, Kelly J, Henshall S, Bacino D, Dietz M, Hogue R, Koelsch G, Nightingale L, Shaver T, Abdou NI, Albert DA, Carson C, Petri M, Treadwell EL, James JA, Harley JB. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. *Proc Natl Acad Sci U S A* 1998; **95**: 14869-14874 [PMID: [9843982](#) DOI: [10.1073/pnas.95.25.14869](#)]
- 12 **Cantor RM**, Yuan J, Napier S, Kono N, Grossman JM, Hahn BH, Tsao BP. Systemic lupus erythematosus genome scan: support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23. *Arthritis Rheum* 2004; **50**: 3203-3210 [PMID: [15476245](#) DOI: [10.1002/art.20511](#)]
- 13 **Pereira Da Silva JA**, Elkon KB, Hughes GR, Dyck RF, Pepys MB. C-reactive protein levels in systemic lupus erythematosus: a classification criterion? *Arthritis Rheum* 1980; **23**: 770-771 [PMID: [7387742](#) DOI: [10.1002/art.1780230609](#)]
- 14 **Li QY**, Li HY, Fu G, Yu F, Wu Y, Zhao MH. Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis. *J Am Soc Nephrol* 2017; **28**: 3044-3054 [PMID: [28566480](#) DOI: [10.1681/ASN.2016070735](#)]
- 15 **Bell SA**, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. *Clin Exp Immunol* 1998; **113**: 327-332 [PMID: [9737658](#) DOI: [10.1046/j.1365-2249.1998.00655.x](#)]
- 16 **Sjögwall C**, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease. *J Autoimmun* 2002; **19**: 155-160 [PMID: [12419286](#) DOI: [10.1006/jaut.2002.0608](#)]
- 17 **Rodriguez W**, Mold C, Kataranovsk M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. *Arthritis Rheum* 2005; **52**: 642-650 [PMID: [15692982](#) DOI: [10.1002/art.20846](#)]
- 18 **Szalai AJ**, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF, Marion TN, Volanakis JE. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. *Arthritis Rheum* 2003; **48**: 1602-1611 [PMID: [12794828](#) DOI: [10.1002/art.11026](#)]
- 19 **Szalai AJ**, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. *J Mol Med (Berl)* 2005; **83**: 440-447 [PMID: [15778807](#) DOI: [10.1007/s00109-005-0658-0](#)]
- 20 **Russell AI**, Cunningham Graham DS, Shepherd C, Robertson CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. *Hum Mol Genet* 2004; **13**: 137-147 [PMID: [14645206](#) DOI: [10.1093/hmg/ddh021](#)]
- 21 **Atisha-Fregoso Y**, Lima G, Carrillo-Maravilla E, Posadas-Sánchez R, Pérez-Hernández N, Baños-Peláez M, Iturralde-Chávez A, Hernández-Díaz N, Jakez-Ocampo J, Rodríguez-Pérez JM, Vargas-Alarcón G, Llorente L, Romero-Díaz J. C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population. *Clin Rheumatol* 2018; **37**: 1817-1824 [PMID: [29556849](#) DOI: [10.1007/s10067-018-4059-5](#)]
- 22 **Delongui F**, Lozovoy MAB, Iriyoda TMV, Costa NT, Stadtlober NP, Alfieri DF, Flauzino T, Dichi I, Simão ANC, Reiche EMV. C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels. *Clin Rheumatol* 2017; **36**: 1779-1788 [PMID: [28567557](#) DOI: [10.1007/s10067-018-4059-5](#)]



- 10.1007/s10067-017-3695-5]
- 23 **Kim HA**, Chun HY, Kim SH, Park HS, Suh CH. C-reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. *J Rheumatol* 2009; **36**: 2238-2243 [PMID: [19755616](#) DOI: [10.3899/jrheum.090243](#)]
- 24 **Shih PB**, Manzi S, Shaw P, Kenney M, Kao AH, Bontempo F, Barmada MM, Kammerer C, Kamboh MI. Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. *J Rheumatol* 2008; **35**: 2171-2178 [PMID: [18793001](#) DOI: [10.3899/jrheum.080262](#)]
- 25 **Wang FM**, Yu F, Tan Y, Song D, Zhao MH. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. *Rheumatology (Oxford)* 2012; **51**: 2269-2277 [PMID: [22956549](#) DOI: [10.1093/rheumatology/kes218](#)]
- 26 **Fijen CA**, Kuijper EJ, Te Bulte M, van de Heuvel MM, Holdrinet AC, Sim RB, Daha MR, Dankert J. Heterozygous and homozygous factor H deficiency states in a Dutch family. *Clin Exp Immunol* 1996; **105**: 511-516 [PMID: [8809142](#) DOI: [10.1046/j.1365-2249.1996.d01-777.x](#)]
- 27 **Sánchez-Corral P**, Bellavia D, Amico L, Brai M, Rodríguez de Córdoba S. Molecular basis for factor H and FHL-1 deficiency in an Italian family. *Immunogenetics* 2000; **51**: 366-369 [PMID: [10803850](#) DOI: [10.1007/s002510050631](#)]
- 28 **Rodríguez de Córdoba S**, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. *Mol Immunol* 2004; **41**: 355-367 [PMID: [15163532](#) DOI: [10.1016/j.molimm.2004.02.005](#)]
- 29 **Zhao J**, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME; BIOLUPUS Network; GENLES Network, Pons-Estel BA, Harley JB, Bae SC, Bang SY, Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, Alarcon GS, Petri MA, Ramsey-Goldman R, Vilá LM, Reville JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya JM, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Guthridge JM, Chang DM, Song YW, Park JA, Lee EY, Boackle SA, Grossman JM, Hahn BH, Goodship TH, Cantor RM, Yu CY, Shen N, Tsao BP. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. *PLoS Genet* 2011; **7**: e1002079 [PMID: [21637784](#) DOI: [10.1371/journal.pgen.1002079](#)]
- 30 **Li Q**, Song D, Wang F, Tan Y, Yu F, Zhao M. Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. *ScientificWorldJournal* 2014; **2014**: 212597 [PMID: [24672300](#) DOI: [10.1155/2014/212597](#)]
- 31 **Liang MH**, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. *Arthritis Rheum* 1989; **32**: 1107-1118 [PMID: [2775320](#) DOI: [10.1002/anr.1780320909](#)]
- 32 **Bombardier C**, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992; **35**: 630-640 [PMID: [1599520](#) DOI: [10.1002/art.1780350606](#)]
- 33 **Huang J**, Han SS, Qin DD, Wu LH, Song Y, Yu F, Wang SX, Liu G, Zhao MH. Renal Interstitial Arteriosclerotic Lesions in Lupus Nephritis Patients: A Cohort Study from China. *PLoS One* 2015; **10**: e0141547 [PMID: [26544865](#) DOI: [10.1371/journal.pone.0141547](#)]
- 34 **Song D**, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH. The spectrum of renal thrombotic microangiopathy in lupus nephritis. *Arthritis Res Ther* 2013; **15**: R12 [PMID: [23320601](#) DOI: [10.1186/ar4142](#)]
- 35 **Weening JJ**, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int* 2004; **65**: 521-530 [PMID: [14717922](#) DOI: [10.1111/j.1523-1755.2004.00443.x](#)]
- 36 **Shi YY**, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. *Cell Res* 2005; **15**: 97-98 [PMID: [15740637](#) DOI: [10.1038/sj.cr.7290272](#)]
- 37 **Schaumberg DA**, Christen WG, Kozlowski P, Miller DT, Ridker PM, Zee RY. A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2006; **47**: 2336-2340 [PMID: [16723442](#) DOI: [10.1167/iovs.05-1456](#)]
- 38 **Molins B**, Fuentes-Prior P, Adán A, Antón R, Arostegui JI, Yagüe J, Dick AD. Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. *Sci Rep* 2016; **6**: 22889 [PMID: [26961257](#) DOI: [10.1038/srep22889](#)]
- 39 **Rhodes B**, Fürtrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. *Nat Rev Rheumatol* 2011; **7**: 282-289 [PMID: [21468143](#) DOI: [10.1038/nrrheum.2011.37](#)]
- 40 **Rhodes B**, Wong A, Navarra SV, Villamin C, Vyse TJ. Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families. *Genes Immun* 2008; **9**: 153-160 [PMID: [18216863](#) DOI: [10.1038/sj.gene.6364459](#)]
- 41 **Tan M**, Hao JB, Chu H, Wang FM, Song D, Zhu L, Yu F, Li YZ, Song Y, Zhao MH. Genetic variants in FH are associated with renal histopathologic subtypes of lupus nephritis: a large cohort study from China. *Lupus* 2017; **26**: 1309-1317 [PMID: [28403670](#) DOI: [10.1177/0961203317702254](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

